Onkologie. 2025:19(5):283-287 | DOI: 10.36290/xon.2025.051

Actual possibilities of target therapy for Non-Small Cell Lung Cancer in Czech Republic

Monika Bratová
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Lékařská fakulta, Masarykova univerzita, Brno

Target therapy od non-small cell lung cancer (NSCLC) has experienced further huge development in last years. There were new agents introduced into clinical practice (RET, KRAS, MET, ROS1, BRAF inhibitors, HER2 blocker). Also indication of this therapy spreads into the adjuvant use (osimertinib, alectinib) or into the combination with chemotherapy (osimertinib). An important change of clinical practise is caused by amivantamab, that proved effectivity in the treatment of NSCLC with sensitising mutations or in NSCLC with EGFR insertion in exon 20. This progress leads to the further precise personalization of the treatment of NSCLC with driving mutations. This group is now divided into several subtypes suitable to individual treatment.

Keywords: target therapy, non-small cell lung cancer, driving mutations.

Accepted: November 25, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bratová M. Actual possibilities of target therapy for Non-Small Cell Lung Cancer in Czech Republic. Onkologie. 2025;19(5):283-287. doi: 10.36290/xon.2025.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 15.12.2026

    References

    1. Cancer today [Internet]. Globocan 2022; c2025. [cited 2025 August 18]. Available from: https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&group_populations=1.
    2. Novotvary 2019-2021[Internet]. ÚZIS. c2025. [cited 2025 August 18]. Available from: https://www.uzis.cz/res/f/008447/novotvary2019-2021.pdf.
    3. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [Internet]. ESMO. c2025. [cited 2025 August 18]. Available from: https://www.annalsofoncology.org/article/S0923-7534(22)04781-0/fulltext.
    4. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31. Erratum in: J Clin Oncol. 2023;41(22):3877. Go to original source... Go to PubMed...
    5. Wu YL, Dziadziuszko R, Ahn JS. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390(14):1265-1276. Go to original source... Go to PubMed...
    6. Zhoubný novotvar bronchu, plíce, pleury a thymu [Internet]. Modrá kniha. c2025. [cited 2025 August 18]. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/31-8-zhoubny-novotvar-bronchu-plice-pleury-a-thymu-c34-c33-c37/.
    7. Landre T, Assié JB, Chouahnia K. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. Expert Rev Anticancer Ther. 2024;24(8):775-780. Go to original source... Go to PubMed...
    8. Passaro A, Wang J, Wang Y. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90. Go to original source... Go to PubMed...
    9. Zhou C, Tang KJ, Cho BC, et al. PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389(22):2039-2051. Go to original source... Go to PubMed...
    10. Mamesaya N, Mori K, Kobayashi H. Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing. Int J Clin Oncol. 2025 Jul 6. Go to original source... Go to PubMed...
    11. Solomon BJ, Liu G, Felip E. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024;42(29):3400-3409. Go to original source... Go to PubMed...
    12. Zhou C, Lu Y, Kim SW, et al. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. JTO Clin Res Rep. 2024;5(9):100700. Go to original source... Go to PubMed...
    13. de Langen AJ, Johnson ML, Mazieres J, et al. CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733-746. Go to original source... Go to PubMed...
    14. Johnson ML, Smit EF, Felip E, et al. Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus
    15. Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024;391(7):585-597. Go to original source... Go to PubMed...
    16. Tsuboi M, Weder W, Escriu C. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: Neo­ADAURA. Future Oncol. 2021;17(31):4045-4055. Go to original source... Go to PubMed...
    17. Lee SH, Lu S, Hayashi H. Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. J Thorac Oncol. 2025:S1556-0864(25)00821-4.
    18. Papassotiriou I, Tentolouris A, Liontos M. Cardiac and vascular toxicity of amivantamab in non-small cell lung cancer (NSCLC): A systematic review. Crit Rev Oncol Hematol. 2025:104835. Go to original source... Go to PubMed...
    19. Stumpo S, Carlini A, Mantuano F. Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data. Cancers (Basel). 2025;17(11):1750. Go to original source... Go to PubMed...
    20. Bratova M, Karlinova B, Skrickova J. Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry. In Vivo. 2020;34(1):369-379. Go to original source... Go to PubMed...
    21. Behinaein P, Gadgeel SM, Rattan R. Resistance mechanisms in anaplastic lymphoma kinase-positive lung cancer. Crit Rev Oncol Hematol. 2025;214:104821. Go to original source... Go to PubMed...
    22. Attili I, Corvaja C, Trillo Aliaga P. Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions. Cancer Treat Rev. 2025;137:102957. Go to original source... Go to PubMed...
    23. Wu YL, Guarneri V, Voon PJ, et al. INSIGHT 2 investigators. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Erratum in: Lancet Oncol. 2024;25(10):e472. doi: 10.1016/S1470-2045(24)00509-6. PMID: 39089305. Go to original source... Go to PubMed...
    24. Joshi A, Bhaskar N, Pearson JD. Neuroendocrine Transformation as a Mechanism of Resistance to Targeted Lung Cancer Therapies: Emerging Mechanisms and Their Therapeutic Implications. Cancers (Basel). 2025;17(2):260. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.